Citrulline modified peptide antigen combination and application thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of citrulline and peptide antigen, applied in the field of biomedicine
Active Publication Date: 2018-12-07
BEIJING PROTEOME RES CENT
View PDF7 Cites 3 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
But the diagnostic specificity of these
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0108] Synthesis of embodiment 1 citrulline modified peptide
[0109] 1. The sequence of the citrulline modified peptide is as follows:
[0110] GSGMSNP-(Cit)-SLEEEKY (SEQ ID NO: 1)
[0111] RLAADDF-(Cit)-LKYENEV (SEQ ID NO: 2)
[0112] NLNGGLL-(Cit)-GIEILNQ (SEQ ID NO: 3)
[0113] 2. Synthesis sequence: from the C-terminal to the N-terminal of the sequence, the steps are as follows:
[0114] 1) Weigh 0.3g of resin into a glass reactor, add DCM (dichloromethane) to swell for 30 minutes;
[0115] 2) Take out the DCM, add 0.6g of the first amino acid in the amino acid sequence, add 0.6g of DIEA (diisopropylethylamine), DMF (dimethylformamide), DCM, react by bubbling nitrogen for 60 minutes, and take out The reaction solution was washed three times by adding DMF and MEOH;
[0116] 3) Add 0.6 g of the second amino acid in the amino acid sequence to the reactor, add HBTH (1-hydroxyl, benzo, tricloxazole tetramethylhexafluorophosphate) and DIEA, react with nitrogen gas bubbling...
Embodiment 2
[0124] Example 2 Application of citrulline-modified peptides based on microsphere detection technology in the detection of patients with CCP-negative rheumatoid arthritis 1. Experimental materials and reagents
[0125] 1) Activation buffer: 0.1M NaH 2 PO 4 (Sigma-Aldrich, St. Louis, MO, USA), pH 6.2;
[0126]2) EDC solution: 50mg / mL EDC (1-ethyl-3-[3-dimethylaminopropyl]carbodiimidehydrochloride, Thermo Fisher Scientific, IL, USA);
[0127] 3) Sulfo-NHS solution: 50 mg / ml sulfo-NHS (Thermo Fisher Scientific, IL, USA);
[0132] 8) Detection antibody: Alexa555-labeled anti-human IgG or anti...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention provides a citrulline modified peptide antigen combination and a composition comprising the citrulline modified peptide antigen combination. The invention also provides the use of the citrulline modified peptide antigen combination or the composition comprising the citrulline modified peptide antigen combination in preparation of a diagnostic tool detecting anti-citrulline modified peptide IgG antibodies and/or IgA antibodies. The citrulline modified peptide antigen combination provided by the invention is used for detecting IgG antibodies and/or IgA antibody markers, and solvesthe problem that 30% of clinical RA (rheumatoid arthritis) patients lack clear markers. The diagnostic tool provided by the invention adopts an antigen combination corresponding to the autoantibody ofa novel rheumatoid arthritis related biomarker to detect the autoantibody in human serum, has the advantages of good specificity, high sensitivity, good accuracy, wide linear range, safety, reliability and easy operation, and is especially suitable for screening and diagnosis of negative rheumatoid arthritis patients non-detectable by current clinical CCP2 (cyclic citrullinated peptide 2).
Description
technical field [0001] The invention relates to the field of biomedical technology, in particular to anti-citrulline-modified peptide IgG antibody and / or IgA antibody serological detection technology, in particular to citrulline-modified peptide antigen, diagnostic tool or its preparation method and CCP-negative rheumatoid Application of autoantibody detection in arthritis patients. Background technique [0002] Rheumatoid arthritis (RA, Rheumatoid Arthritis) is one of the most common systemic autoimmune diseases, which affects about 0.5-1% of the population worldwide. RA is a systemic autoimmune disease. Patients are often accompanied by chronic joint inflammation and suffer from a chronic course of the disease, which can lead to progressive joint destruction, bone erosion, and deformity. The most important serological finding of RA in rheumatoid arthritis is the presence of autoantibodies that specifically recognize citrulline-modified proteins in patient sera. About 70%...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more